Your session is about to expire
← Back to Search
OMS721 for Immunoglobulin A Nephropathy
Study Summary
This trial will study the drug OMS721 in patients with IgA nephropathy to see if it is safe and effective. The study will look at how much protein is in the urine after 36 weeks of treatment.
- Immunoglobulin A Nephropathy
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Have other research teams attempted anything like this previously?
"Currently, there are 2 ongoing studies for OMS721 across 10 countries and 45 cities. The earliest study was completed in 2018 by 450 participants.Sponsored by Omeros Corporation, this trial reached Phase 3 drug approval and 1 more trials have been conducted since then."
What is the maximum number of patients who can enroll in this trial?
"That is correct. The information available on clinicaltrials.gov reveals that this particular trial is still recruiting patients. This specific study was originally posted on February 16th, 2018 and was most recently updated on May 28th, 2019. In total, they are looking for 450 participants spread out over 21 different locations."
Are researchers actively seeking participants for this trial?
"That is correct, the information available on clinicaltrials.gov reveals that this particular trial is looking for new patients. This specific trial was created on 2/16/2018 and updated as recently as 5/28/2019. In total, they are seeking 450 participants from 21 different locations."
Are there several sites running this trial in the city?
"To make things as convenient as possible for the patients, this clinical trial is enrolling at 21 locations. These medical centres are situated in Albuquerque, Minneapolis, Columbus and 18 other cities. Consequently, when deciding whether or not to participate, please consider how close the sites are to your residence."
Are there any life-threatening risks associated with OMS721?
"OMS721 is in Phase 3 of clinical trials, so there is some data supporting efficacy and multiple rounds of data supporting safety."
What is the history of research on OMS721?
"There are two ongoing clinical trials researching the efficacy of OMS721. One of these live studies is in Phase 3. The majority of research for this treatment is being conducted in Vilnius and Washington, but there are 60 total locations running trials."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger